Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2021 (Event Date)
Reporting Period: The filing primarily addresses a material definitive agreement entered into on August 6, 2021, and references financial results for the fiscal second quarter ended June 30, 2021, which were announced via press release on August 9, 2021.
Key Financial Metrics and Debt Structure
New Debt Facility (August 6, 2021):
- Term Loan Facility: Up to $75,000,000.
- Revolving Credit Facility: Up to $125,000,000.
- Total Debt Facility: Up to $200,000,000.
- Interest Rates: Variable based on Total Net Leverage Ratio (LIBOR + 2.00% to 3.25% for Eurodollar Loans; Prime/Fed Funds + 1.00% to 2.25% for ABR Loans).
- Term Loan Maturity: August 6, 2026.
- Revolving Termination Date: August 6, 2026.
Financial Covenants:
- Fixed Charge Coverage Ratio: Minimum 1.25:1.00.
- Total Net Leverage Ratio: Maximum 3.50:1.00 (through Q3 2022), stepping down to 3.25:1.00 (through Q3 2023), and 3.00:1.00 thereafter.
Cost of Termination: Approximately $4.2 million in prepayment premiums, rollover anniversary fees, and exit fees paid to terminate the prior credit facility.
Revenue, Profit, and Cash Flow: The filing text does not provide specific numerical values for revenue, profit, or cash flow. These figures are referenced as being contained in a press release (Exhibit 99.1) incorporated by reference.
Material Changes Versus Prior Period
- Debt Restructuring: The Company terminated its prior credit agreement (dated March 14, 2019) and replaced it with a new, larger facility ($200 million total capacity vs. the prior facility).
- Liquidity Impact: Proceeds from the new facility were used to repay the prior facility in full and for general corporate purposes.
- Shareholder Restrictions: Legacy stockholders (holding >40% of outstanding capital stock) agreed to a lock-up restriction preventing sales until at least March 1, 2022, unless part of an underwritten secondary offering.
Guidance, Outlook, and Risks
Management Commentary and Use of Proceeds: The Company intends to use proceeds for general corporate purposes and repayment of the prior credit facility. No specific forward-looking financial guidance (e.g., revenue targets) is provided in the text of this filing.
Risks and Contingencies:
- Covenant Compliance: The Company must maintain specific leverage and coverage ratios; failure to do so constitutes an event of default.
- Prepayment Penalties: Prepayments of the Term Loan prior to August 6, 2022, incur a 1.00% premium. Reduction of the Revolving Facility prior to the same date also incurs a 1.00% fee.
- Collateral: Obligations are secured by substantially all of the Company's assets, including intellectual property.
- Restrictions: The agreement restricts dividends, stock repurchases, additional indebtedness, and asset dispositions.
Key Facts for Investor Verification
- Verify the specific Q2 2021 revenue and net income figures in the press release (Exhibit 99.1) referenced but not detailed in this text.
- Confirm the current Total Net Leverage Ratio to assess proximity to the 3.50:1.00 covenant ceiling.
- Review the full Credit Agreement (Exhibit 10.1) for detailed definitions of "Total Net Leverage Ratio" and "Fixed Charge Coverage Ratio."
- Monitor the $4.2 million one-time cost impact on the Company's cash flow and earnings for the period.
- Track the lock-up expiration date of March 1, 2022, for potential selling pressure from legacy stockholders.